poisar

Stocks · News reference

HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65

Benzinga Newsdesk

HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BMY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY
  2. Zacks.Com

    How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

    With traditional fixed-income investments yielding lower returns and Social Security facing potential depletion by 2035, retirees should consider dividend-paying stocks from high-quality companies as an alternative income source. The article highlights three dividend stocks suitable for retirement portfolios and explains how dividend growth can help combat inflation while reducing overall portfolio volatility compared to bonds.

    BMYCELGRIVTSFNC
  3. Not Specified

    Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network

    Onco360, the nation's leading independent specialty pharmacy, has been selected by Bristol-Myers Squibb as a participating pharmacy in the limited dispense network for ZENBEXUS™ (iberdomide), a cereblon-modulating protein degrader used to treat relapsed or refractory multiple myeloma. The drug demonstrated a 41% MRD-negative complete response rate in the EXCALIBER-RRMM trial compared to 21% in the comparator arm.

    BMYCELGR
  4. Na

    Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

    Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.

    BMYCELGRAMGNTAK